David M Nudell, MD
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 7 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
24 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nudell’s office at (408) 871-5220 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A60360 · Current
Licensed to practise in California · since 1996 · expires 2028-04-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Los Gatos Surgical CenterAmbulatory Surgery Center · Los Gatos, CA0.27% owner since 2013 · accredited by AAAHCAccreditation Renewed6 inspections, 3 with deficiencies · last 2025-04-03
- Los Gatos Surgical CenterSan Jose, CA0.27% owner since 2013 · accredited by AAAHCClosed1 inspection · last 2021-08-10
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$428,936
Medicare paid this office $428,936 for 594 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 466 | $96,136 | $113 |
| Detection test by nucleic acid for organism, amplified probe technique | 152 | $58,186 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 151 | $43,468 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $22,235 | None |
| New patient visit (45+ min) | 117 | $16,524 | $141 |
See all 36 services
| Return visit (30+ min) | 466 | $96,136 | $113 |
| Detection test by nucleic acid for organism, amplified probe technique | 152 | $58,186 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 151 | $43,468 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $22,235 | None |
| New patient visit (45+ min) | 117 | $16,524 | $141 |
| Diagnostic exam of bladder and urethra using an endoscope | 40 | $11,864 | $242 |
| Complete ultrasound scan of pelvis | 92 | $9,888 | $104 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 23 | $8,793 | $382 |
| Complete ultrasound scan behind abdominal cavity | 75 | $8,637 | $105 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 152 | $7,325 | $34 |
| Detection test for candida species (yeast), amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 152 | $7,325 | $34 |
| Detection of mycoplasma genitalium by dna or rna probe | 152 | $7,325 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 152 | $7,325 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 152 | $7,325 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 352 | $5,658 | $11 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 15 | $5,152 | $322 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 199 | $3,720 | $15 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 68 | $3,680 | $34 |
| Complicated insertion of bladder tube | 11 | $3,408 | $136 |
| Urinalysis, manual test | 451 | $2,684 | $3 |
| Short return visit | 40 | $2,678 | $51 |
| Long return visit (40+ min) | 14 | $2,415 | $172 |
| Short return visit (20+ min) | 23 | $2,028 | $88 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,608 | $124 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,607 | $36 |
| Manual urinalysis test with examination using microscope, non-automated | 130 | $630 | $4 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 11 | $510 | $42 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $292 | $24 |
| Other procedure on urinary system | 12 | $254 | $21 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $240 | $22 |
| Electronic assessment of bladder emptying | 20 | $214 | $10 |
Procedures Medicare counted
| Prostate resection | 12 | More than 62% of doctors who do this |
Who their Medicare patients are
594 Original Medicare patients in 2024. Average age 77 · Women 20% · Also on Medicaid 3% · Health risk score 1.07. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 33% · Diabetes 31% · Cancer 24% · Atrial fibrillation 23% · Chronic kidney disease 21% · Heart failure 13% · Depression 13% · Stroke 11% · COPD 9% · Dementia 7%.
The office billed $1,544,808, Medicare allowed $509,036 and paid $428,936; for 15,700 services of 95 kinds; $29,935 of it was for drugs given in the office and $399,001 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 594 | 15,700 | 77 | 1.07 | $1,544,808 | $428,936 |
| 2023 | 568 | 13,468 | 77 | 1.07 | $905,642 | $385,718 |
| 2022 | 575 | 8,768 | 77 | 1.07 | $640,797 | $232,276 |
| 2021 | 564 | 9,378 | 77 | 1.11 | $625,683 | $226,850 |
| 2020 | 512 | 8,468 | 76 | 1.09 | $598,971 | $198,241 |
| 2019 | 573 | 8,900 | 76 | 1.11 | $709,148 | $235,336 |
| 2018 | 521 | 8,830 | 76 | 1.17 | $559,567 | $184,958 |
| 2017 | 520 | 10,147 | 76 | 1.11 | $644,322 | $205,360 |
| 2016 | 503 | 14,063 | 75 | 1.12 | $621,658 | $206,818 |
| 2015 | 455 | 13,905 | 75 | 1.12 | $616,407 | $211,838 |
| 2014 | 418 | 2,732 | 75 | 1.07 | $443,138 | $157,659 |
| 2013 | 409 | 1,764 | 75 | 1.06 | $398,544 | $139,034 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Return visit (30+ min) | 447 | $81,296 | $110 |
| Detection test by nucleic acid for organism, amplified probe technique | 130 | $53,406 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 125 | $38,073 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $22,260 | None |
| New patient visit (45+ min) | 95 | $13,541 | $143 |
| Diagnostic exam of bladder and urethra using an endoscope | 33 | $9,496 | $232 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 19 | $7,345 | $387 |
| Complete ultrasound scan of pelvis | 71 | $7,342 | $98 |
| Complete ultrasound scan behind abdominal cavity | 60 | $7,200 | $104 |
| Detection test for candida species (yeast), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 130 | $6,637 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 129 | $6,603 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 130 | $6,603 | $34 |
| Detection of mycoplasma genitalium by dna or rna probe | 120 | $6,121 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 367 | $5,731 | $11 |
| Long return visit (40+ min) | 27 | $5,158 | $152 |
| Short return visit | 46 | $4,460 | $54 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 67 | $3,714 | $34 |
| Manual urinalysis test with examination using microscope, non-automated | 504 | $3,534 | $4 |
| Short return visit (20+ min) | 22 | $2,022 | $78 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,786 | $34 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 14 | $442 | $32 |
| Electronic assessment of bladder emptying | 25 | $203 | $8 |
2022: 24 services
| Return visit (30+ min) | 440 | $83,468 | $106 |
| New patient visit (45+ min) | 132 | $18,569 | $141 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $16,268 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 50 | $14,589 | $247 |
| Complete ultrasound scan behind abdominal cavity | 64 | $7,464 | $93 |
| Detection test by nucleic acid for organism, amplified probe technique | 19 | $7,118 | $34 |
| Complete ultrasound scan of pelvis | 68 | $6,864 | $92 |
| Ultrasound measurement of bladder capacity after voiding | 337 | $5,102 | $10 |
| Manual urinalysis test with examination using microscope, non-automated | 504 | $3,794 | $4 |
| Short return visit | 57 | $3,781 | $53 |
| Simple bladder irrigation and/or instillation | 14 | $2,388 | $66 |
| Short return visit (20+ min) | 23 | $1,890 | $82 |
| Long return visit (40+ min) | 11 | $1,777 | $162 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,014 | $32 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 20 | $825 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 20 | $825 | $34 |
| Detection test for candida species (yeast), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 19 | $791 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 19 | $791 | $34 |
| Electronic assessment of bladder emptying | 21 | $207 | $10 |
2021: 16 services
| Return visit (30+ min) | 453 | $88,935 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 61 | $20,149 | $240 |
| New patient visit (45+ min) | 105 | $15,434 | $147 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $12,129 | None |
| Complete ultrasound scan behind abdominal cavity | 67 | $9,042 | $113 |
| Complete ultrasound scan of pelvis | 76 | $7,519 | $96 |
| Ultrasound measurement of bladder capacity after voiding | 322 | $4,747 | $10 |
| Manual urinalysis test with examination using microscope, non-automated | 496 | $3,896 | $4 |
| Short return visit | 44 | $3,691 | $55 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 12 | $3,592 | $299 |
| Short return visit (20+ min) | 29 | $2,523 | $84 |
| Long return visit (40+ min) | 11 | $1,563 | $142 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $866 | $33 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $254 | $23 |
| Electronic assessment of bladder emptying | 16 | $246 | $14 |
| Imaging guidance for procedure, 60 minutes or less | 12 | $167 | $14 |
2020: 20 services
| Return visit (30+ min) | 432 | $74,157 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 63 | $14,363 | $208 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $13,772 | None |
| New patient visit (45+ min) | 75 | $10,162 | $135 |
| Complete ultrasound scan behind abdominal cavity | 55 | $7,369 | $115 |
| Complete ultrasound scan of pelvis | 46 | $5,072 | $99 |
| Complicated insertion of bladder tube | 18 | $4,938 | $123 |
| Ultrasound measurement of bladder capacity after voiding | 292 | $4,282 | $10 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 13 | $3,782 | $291 |
| Short return visit (20+ min) | 44 | $3,235 | $72 |
| Manual urinalysis test with examination using microscope, non-automated | 433 | $3,217 | $4 |
| Short return visit | 26 | $1,798 | $43 |
| Biopsy of prostate gland | 14 | $1,682 | $120 |
| Long return visit (40+ min) | 11 | $1,672 | $129 |
| New patient visit (30+ min) | 11 | $1,140 | $104 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $792 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $718 | $24 |
| Ultrasound scan of pelvic region through rectum | 14 | $437 | $31 |
| Ultrasonic guidance for needle placement | 12 | $349 | $29 |
| Electronic assessment of bladder emptying | 12 | $167 | $14 |
2019: 19 services
| Return visit (30+ min) | 479 | $92,942 | $96 |
| Diagnostic exam of bladder and urethra using an endoscope | 83 | $18,899 | $182 |
| New patient visit (45+ min) | 126 | $17,619 | $140 |
| Complete ultrasound scan behind abdominal cavity | 68 | $9,247 | $111 |
| Complete ultrasound scan of pelvis | 65 | $6,508 | $94 |
| Ultrasound measurement of bladder capacity after voiding | 308 | $6,071 | $13 |
| Manual urinalysis test with examination using microscope, non-automated | 517 | $4,330 | $4 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,495 | $318 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $3,490 | $291 |
| Short return visit (20+ min) | 40 | $2,925 | $66 |
| Long return visit (40+ min) | 14 | $1,922 | $128 |
| Short return visit | 20 | $1,731 | $41 |
| Biopsy of prostate gland | 15 | $1,657 | $110 |
| Injection of drug or substance under skin or into muscle | 14 | $932 | $16 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 11 | $467 | $42 |
| Ultrasound scan of pelvic region through rectum | 14 | $429 | $31 |
| Ultrasonic guidance for needle placement | 14 | $406 | $29 |
| Electronic assessment of bladder emptying | 22 | $320 | $14 |
| Imaging guidance for procedure, 60 minutes or less | 12 | $181 | $13 |
2018: 11 services
| Return visit (30+ min) | 438 | $75,235 | $92 |
| New patient visit (45+ min) | 110 | $15,053 | $137 |
| Diagnostic exam of bladder and urethra using an endoscope | 68 | $12,016 | $154 |
| Complete ultrasound scan behind abdominal cavity | 64 | $7,757 | $114 |
| Complete ultrasound scan of pelvis | 56 | $5,876 | $98 |
| Ultrasound measurement of bladder capacity after voiding | 232 | $5,491 | $16 |
| Manual urinalysis test with examination using microscope, non-automated | 463 | $3,414 | $4 |
| Short return visit | 51 | $3,197 | $39 |
| Simple bladder irrigation and/or instillation | 11 | $1,786 | $71 |
| Short return visit (20+ min) | 26 | $1,786 | $66 |
| Electronic assessment of bladder emptying | 34 | $481 | $14 |
2017: 20 services
| Return visit (30+ min) | 419 | $73,805 | $90 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $16,482 | None |
| New patient visit (45+ min) | 95 | $12,901 | $136 |
| Diagnostic exam of bladder and urethra using an endoscope | 64 | $11,205 | $156 |
| Complete ultrasound scan behind abdominal cavity | 69 | $8,046 | $107 |
| Complete ultrasound scan of pelvis | 75 | $7,324 | $94 |
| Short return visit (20+ min) | 71 | $6,021 | $62 |
| Ultrasound measurement of bladder capacity after voiding | 206 | $5,296 | $18 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,812 | $347 |
| Manual urinalysis test with examination using microscope, non-automated | 447 | $3,600 | $4 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $3,321 | $277 |
| Complicated insertion of bladder tube | 14 | $2,793 | $107 |
| Long return visit (40+ min) | 20 | $2,546 | $127 |
| Short return visit | 40 | $2,360 | $40 |
| Injection of drug or substance under skin or into muscle | 23 | $1,920 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $859 | $30 |
| Electronic assessment of bladder emptying | 26 | $444 | $15 |
| Ultrasound scan of pelvic region through rectum | 11 | $335 | $30 |
| Injection, testosterone cypionate, 1 mg | 14 | $111 | None |
| Imaging guidance for procedure, 60 minutes or less | 12 | $92 | $8 |
2016: 18 services
| Return visit (30+ min) | 412 | $77,805 | $89 |
| Diagnostic exam of bladder and urethra using an endoscope | 64 | $14,224 | $187 |
| New patient visit (45+ min) | 99 | $12,852 | $130 |
| Complete ultrasound scan behind abdominal cavity | 77 | $8,953 | $104 |
| Ultrasound measurement of bladder capacity after voiding | 251 | $7,186 | $17 |
| Complete ultrasound scan of pelvis | 85 | $6,910 | $78 |
| Short return visit (20+ min) | 70 | $6,419 | $62 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 20 | $4,779 | $208 |
| Long return visit (40+ min) | 35 | $4,367 | $125 |
| Manual urinalysis test with examination using microscope, non-automated | 374 | $2,949 | $4 |
| Injection of drug or substance under skin or into muscle | 19 | $2,336 | $23 |
| Short return visit | 35 | $1,997 | $39 |
| Simple bladder irrigation and/or instillation | 11 | $1,240 | $65 |
| Ultrasound scan of pelvic region through rectum | 11 | $1,183 | $91 |
| Ultrasound scan of scrotum | 11 | $1,018 | $64 |
| Automated urinalysis test | 211 | $918 | $3 |
| Injection, testosterone cypionate, 1 mg | 16 | $212 | None |
| Electronic assessment of bladder emptying | 16 | $200 | $12 |
2015: 19 services
| Return visit (30+ min) | 386 | $79,373 | $91 |
| Diagnostic exam of bladder and urethra using an endoscope | 78 | $17,972 | $189 |
| New patient visit (45+ min) | 89 | $11,761 | $132 |
| Short return visit (20+ min) | 82 | $7,493 | $62 |
| Complete ultrasound scan behind abdominal cavity | 51 | $5,954 | $110 |
| Long return visit (40+ min) | 43 | $5,930 | $126 |
| Ultrasound measurement of bladder capacity after voiding | 180 | $5,320 | $18 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 20 | $5,255 | $250 |
| Complete ultrasound scan of pelvis | 54 | $4,894 | $86 |
| Complicated insertion of bladder tube | 13 | $2,833 | $123 |
| Automated urinalysis test | 412 | $2,822 | $3 |
| Injection of drug or substance under skin or into muscle | 20 | $2,462 | $24 |
| Ultrasound scan of pelvic region through rectum | 18 | $1,772 | $93 |
| Ultrasound scan of scrotum | 11 | $846 | $60 |
| Ultrasonic guidance for needle placement | 12 | $749 | $58 |
| Cell examination of specimen, selective cellular enhancement technique | 16 | $570 | $36 |
| Short return visit | 12 | $500 | $42 |
| Electronic assessment of bladder emptying | 23 | $340 | $15 |
| Injection, testosterone cypionate, 1 mg | 13 | $232 | None |
2014: 13 services
| Short return visit (20+ min) | 312 | $38,255 | $62 |
| Return visit (30+ min) | 135 | $17,886 | $95 |
| Diagnostic exam of bladder and urethra using an endoscope | 52 | $12,448 | $186 |
| New patient visit (45+ min) | 65 | $8,848 | $136 |
| Complete ultrasound scan behind abdominal cavity | 51 | $7,241 | $127 |
| Complete ultrasound scan of pelvis | 50 | $5,511 | $108 |
| Ultrasound measurement of bladder capacity after voiding | 166 | $4,683 | $18 |
| Long return visit (40+ min) | 28 | $4,534 | $133 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 13 | $2,777 | $214 |
| Automated urinalysis test | 376 | $2,550 | $3 |
| Short return visit | 17 | $955 | $42 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $574 | $17 |
| Electronic assessment of bladder emptying | 23 | $327 | $14 |
2013: 12 services
| Short return visit (20+ min) | 346 | $42,021 | $63 |
| Diagnostic exam of bladder and urethra using an endoscope | 59 | $13,536 | $180 |
| New patient visit (45+ min) | 76 | $10,656 | $140 |
| Return visit (30+ min) | 87 | $8,348 | $83 |
| Complete ultrasound scan behind abdominal cavity | 47 | $7,058 | $131 |
| Complete ultrasound scan of pelvis | 26 | $3,254 | $121 |
| Injection of drug or substance under skin or into muscle | 12 | $2,022 | $24 |
| Ultrasound measurement of bladder capacity after voiding | 72 | $1,889 | $20 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 50 | $1,526 | $19 |
| Ultrasound scan of scrotum | 11 | $1,312 | $119 |
| Automated urinalysis test | 65 | $242 | $3 |
| Electronic assessment of bladder emptying | 16 | $237 | $15 |
Drugs they prescribed that Part D paid
$267,796
Pharmacies billed $267,796 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (24 of 2,278) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
2,062 generic and fewer than 11 brand-name prescriptions · $267,796 in drug cost · 348 antibiotic prescriptions to 150 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 97 | $105,626 | $1,089 |
| Gemtesa | 87 | $79,171 | $910 |
| Tamsulosin | 499 | $10,232 | $21 |
| Finasteride | 483 | $9,878 | $20 |
| Alfuzosin Hcl Er | 186 | $5,221 | $28 |
See all 26 drugs
| Myrbetriq | 97 | $105,626 | $1,089 |
| Gemtesa | 87 | $79,171 | $910 |
| Tamsulosin | 499 | $10,232 | $21 |
| Finasteride | 483 | $9,878 | $20 |
| Alfuzosin Hcl Er | 186 | $5,221 | $28 |
| Potassium Citrate Er | 40 | $4,552 | $114 |
| Oxybutynin Chloride Er | 88 | $3,483 | $40 |
| Testosterone Cypionate | 60 | $3,478 | $58 |
| Testosterone | 36 | $3,013 | $84 |
| Nitrofurantoin | 58 | $2,965 | $51 |
| Solifenacin | 18 | $1,783 | $99 |
| Bicalutamide | 24 | $1,524 | $63 |
| Dutasteride | 49 | $1,513 | $31 |
| Estradiol | 18 | $1,120 | $62 |
| Tolterodine Tartrate Er | 13 | $938 | $72 |
| Cephalexin | 69 | $736 | $11 |
| Nitrofurantoin Mono-Macro | 44 | $708 | $16 |
| Ciprofloxacin | 93 | $637 | $7 |
| Doxazosin Mesylate | 35 | $421 | $12 |
| Terazosin | 22 | $345 | $16 |
| Anastrozole | 40 | $285 | $7 |
| Sulfamethoxazole-Trimethoprim | 44 | $239 | $5 |
| Allopurinol | 14 | $180 | $13 |
| Amoxicillin-Clavulanate Potass | 16 | $139 | $9 |
| Hydrocodone-Acetaminophen | 15 | $100 | $7 |
| Levofloxacin | 12 | $89 | $7 |
Year by year
| 2024 | 2,278 | 535 | 1% (24) | None | $267,796 |
| 2023 | 1,997 | 499 | 1% (18) | None | $294,857 |
| 2022 | 1,876 | 467 | 1% (19) | None | $266,543 |
| 2021 | 1,706 | 409 | 1% (17) | 12% | $229,223 |
| 2020 | 1,622 | 387 | 2% (27) | 13% | $196,493 |
| 2019 | 1,595 | 384 | 2% (30) | None | $208,811 |
| 2018 | 1,428 | 324 | 2% (25) | 22% | $208,775 |
| 2017 | 1,346 | 295 | 3% (36) | 24% | $173,536 |
| 2016 | 1,280 | 265 | 2% (30) | None | $151,302 |
| 2015 | 1,251 | 229 | 1% (18) | 29% | $139,139 |
| 2014 | 1,249 | 239 | 3% (37) | 31% | $142,361 |
| 2013 | 1,034 | 190 | 2% (20) | None | $112,242 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Myrbetriq | 108 | $105,388 | $976 |
| Gemtesa | 92 | $66,612 | $724 |
| Orgovyx | 11 | $27,689 | $2,517 |
| Tamsulosin | 405 | $8,811 | $22 |
| Finasteride | 389 | $7,360 | $19 |
| Alfuzosin Hcl Er | 158 | $5,278 | $33 |
| Potassium Citrate Er | 34 | $4,533 | $133 |
| Testosterone Cypionate | 60 | $2,950 | $49 |
| Testosterone | 35 | $2,863 | $82 |
| Dutasteride | 40 | $2,391 | $60 |
| Oxybutynin Chloride Er | 75 | $2,196 | $29 |
| Solifenacin | 12 | $2,168 | $181 |
| Bicalutamide | 45 | $2,025 | $45 |
| Tolterodine Tartrate Er | 12 | $1,819 | $152 |
| Nitrofurantoin | 30 | $1,251 | $42 |
| Cephalexin | 101 | $1,140 | $11 |
| Estradiol | 12 | $957 | $80 |
| Doxazosin Mesylate | 31 | $810 | $26 |
| Nitrofurantoin Mono-Macro | 31 | $603 | $19 |
| Terazosin | 25 | $449 | $18 |
| Ciprofloxacin | 73 | $419 | $6 |
| Sulfamethoxazole-Trimethoprim | 39 | $363 | $9 |
| Anastrozole | 24 | $127 | $5 |
| Levofloxacin | 15 | $72 | $5 |
2022: 25 drugs
| Myrbetriq | 114 | $122,631 | $1,076 |
| Gemtesa | 46 | $40,355 | $877 |
| Tamsulosin | 401 | $9,695 | $24 |
| Finasteride | 391 | $8,084 | $21 |
| Alfuzosin Hcl Er | 159 | $5,104 | $32 |
| Potassium Citrate Er | 24 | $4,262 | $178 |
| Testosterone Cypionate | 42 | $2,223 | $53 |
| Dutasteride | 34 | $2,215 | $65 |
| Nitrofurantoin | 32 | $2,175 | $68 |
| Testosterone | 21 | $2,165 | $103 |
| Oxybutynin Chloride Er | 37 | $1,879 | $51 |
| Solifenacin | 18 | $1,848 | $103 |
| Estradiol | 18 | $1,668 | $93 |
| Cephalexin | 101 | $1,299 | $13 |
| Nitrofurantoin Mono-Macro | 45 | $905 | $20 |
| Bicalutamide | 16 | $894 | $56 |
| Doxazosin Mesylate | 25 | $721 | $29 |
| Terazosin | 28 | $503 | $18 |
| Ciprofloxacin | 59 | $390 | $7 |
| Clotrimazole-Betamethasone | 20 | $384 | $19 |
| Sulfamethoxazole-Trimethoprim | 50 | $272 | $5 |
| Amoxicillin-Clavulanate Potass | 17 | $138 | $8 |
| Levofloxacin | 35 | $114 | $3 |
| Hydrocodone-Acetaminophen | 17 | $105 | $6 |
| Nystop | 11 | $91 | $8 |
2021: 24 drugs
| Myrbetriq | 118 | $122,794 | $1,041 |
| Toviaz | 14 | $14,288 | $1,021 |
| Finasteride | 368 | $9,586 | $26 |
| Tamsulosin | 341 | $7,947 | $23 |
| Alfuzosin Hcl Er | 156 | $6,284 | $40 |
| Potassium Citrate Er | 21 | $4,075 | $194 |
| Testosterone | 18 | $3,525 | $196 |
| Dutasteride | 42 | $3,307 | $79 |
| Estradiol | 19 | $2,246 | $118 |
| Nitrofurantoin | 30 | $2,190 | $73 |
| Solifenacin | 25 | $2,111 | $84 |
| Oxybutynin Chloride Er | 52 | $1,711 | $33 |
| Testosterone Cypionate | 27 | $1,266 | $47 |
| Cephalexin | 84 | $1,071 | $13 |
| Bicalutamide | 14 | $1,008 | $72 |
| Doxazosin Mesylate | 32 | $891 | $28 |
| Nitrofurantoin Mono-Macro | 27 | $739 | $27 |
| Terazosin | 28 | $671 | $24 |
| Ciprofloxacin | 56 | $301 | $5 |
| Sulfamethoxazole-Trimethoprim | 45 | $210 | $5 |
| Levofloxacin | 26 | $205 | $8 |
| Anastrozole | 16 | $191 | $12 |
| Amoxicillin-Clavulanate Potass | 11 | $137 | $12 |
| Hydrocodone-Acetaminophen | 17 | $127 | $7 |
2020: 25 drugs
| Myrbetriq | 87 | $72,096 | $829 |
| Toviaz | 32 | $22,246 | $695 |
| Finasteride | 336 | $8,770 | $26 |
| Testosterone | 12 | $8,530 | $711 |
| Alfuzosin Hcl Er | 168 | $7,199 | $43 |
| Tamsulosin | 297 | $7,076 | $24 |
| Potassium Citrate Er | 25 | $5,173 | $207 |
| Estradiol | 19 | $3,772 | $199 |
| Dutasteride | 38 | $3,649 | $96 |
| Solifenacin | 38 | $3,236 | $85 |
| Oxybutynin Chloride Er | 72 | $2,823 | $39 |
| Testosterone Cypionate | 30 | $1,923 | $64 |
| Nitrofurantoin | 25 | $1,617 | $65 |
| Cephalexin | 76 | $882 | $12 |
| Terazosin | 23 | $799 | $35 |
| Doxazosin Mesylate | 25 | $695 | $28 |
| Bicalutamide | 12 | $416 | $35 |
| Nitrofurantoin Mono-Macro | 22 | $385 | $17 |
| Levofloxacin | 37 | $299 | $8 |
| Allopurinol | 12 | $226 | $19 |
| Ciprofloxacin | 44 | $223 | $5 |
| Hydrocodone-Acetaminophen | 25 | $174 | $7 |
| Anastrozole | 12 | $144 | $12 |
| Sulfamethoxazole-Trimethoprim | 34 | $128 | $4 |
| Fluconazole | 12 | $67 | $6 |
2019: 26 drugs
| Myrbetriq | 108 | $72,144 | $668 |
| Toviaz | 34 | $18,013 | $530 |
| Elmiron | 15 | $16,594 | $1,106 |
| Vesicare | 16 | $12,583 | $786 |
| Potassium Citrate Er | 46 | $8,649 | $188 |
| Finasteride | 269 | $7,779 | $29 |
| Tamsulosin | 243 | $5,653 | $23 |
| Dutasteride | 49 | $5,483 | $112 |
| Estradiol | 27 | $5,321 | $197 |
| Alfuzosin Hcl Er | 147 | $5,019 | $34 |
| Rapaflo | 15 | $4,197 | $280 |
| Testosterone Cypionate | 43 | $3,104 | $72 |
| Oxybutynin Chloride Er | 51 | $3,008 | $59 |
| Nitrofurantoin | 33 | $2,639 | $80 |
| Solifenacin | 12 | $2,017 | $168 |
| Tolterodine Tartrate Er | 12 | $1,445 | $120 |
| Nitrofurantoin Mono-Macro | 39 | $986 | $25 |
| Cephalexin | 66 | $963 | $15 |
| Doxazosin Mesylate | 24 | $828 | $34 |
| Terazosin | 30 | $579 | $19 |
| Bicalutamide | 12 | $556 | $46 |
| Sulfamethoxazole-Trimethoprim | 67 | $401 | $6 |
| Ciprofloxacin | 42 | $310 | $7 |
| Levofloxacin | 27 | $237 | $9 |
| Hydrocodone-Acetaminophen | 28 | $213 | $8 |
| Anastrozole | 12 | $67 | $6 |
2018: 26 drugs
| Myrbetriq | 117 | $69,248 | $592 |
| Vesicare | 39 | $22,065 | $566 |
| Androgel | 16 | $14,832 | $927 |
| Elmiron | 15 | $14,806 | $987 |
| Toviaz | 12 | $7,837 | $653 |
| Rapaflo | 21 | $7,388 | $352 |
| Potassium Citrate Er | 43 | $6,821 | $159 |
| Finasteride | 237 | $6,112 | $26 |
| Tamsulosin | 193 | $5,618 | $29 |
| Dutasteride | 65 | $5,389 | $83 |
| Nitrofurantoin | 31 | $4,116 | $133 |
| Testosterone | 13 | $4,053 | $312 |
| Alfuzosin Hcl Er | 124 | $3,772 | $30 |
| Oxybutynin Chloride Er | 57 | $2,652 | $47 |
| Estradiol | 12 | $2,504 | $209 |
| Testosterone Cypionate | 34 | $1,646 | $48 |
| Tolterodine Tartrate Er | 11 | $1,187 | $108 |
| Nitrofurantoin Mono-Macro | 36 | $1,159 | $32 |
| Doxazosin Mesylate | 20 | $912 | $46 |
| Bicalutamide | 15 | $640 | $43 |
| Cephalexin | 51 | $596 | $12 |
| Levofloxacin | 27 | $433 | $16 |
| Terazosin | 28 | $409 | $15 |
| Sulfamethoxazole-Trimethoprim | 36 | $254 | $7 |
| Ciprofloxacin | 39 | $234 | $6 |
| Hydrocodone-Acetaminophen | 23 | $169 | $7 |
2017: 24 drugs
| Myrbetriq | 64 | $31,441 | $491 |
| Vesicare | 61 | $30,101 | $493 |
| Rapaflo | 60 | $18,982 | $316 |
| Cialis | 26 | $12,713 | $489 |
| Potassium Citrate Er | 40 | $8,164 | $204 |
| Tamsulosin | 180 | $5,669 | $31 |
| Finasteride | 205 | $5,209 | $25 |
| Dutasteride | 49 | $4,192 | $86 |
| Nitrofurantoin | 36 | $2,957 | $82 |
| Alfuzosin Hcl Er | 91 | $2,315 | $25 |
| Oxybutynin Chloride Er | 39 | $1,883 | $48 |
| Testosterone Cypionate | 29 | $1,837 | $63 |
| Testosterone | 20 | $1,758 | $88 |
| Tolterodine Tartrate Er | 12 | $1,369 | $114 |
| Bicalutamide | 36 | $1,217 | $34 |
| Oxybutynin Chloride | 15 | $1,129 | $75 |
| Nitrofurantoin Mono-Macro | 37 | $967 | $26 |
| Doxazosin Mesylate | 15 | $790 | $53 |
| Cephalexin | 62 | $565 | $9 |
| Levofloxacin | 38 | $541 | $14 |
| Ciprofloxacin | 50 | $303 | $6 |
| Sulfamethoxazole-Trimethoprim | 22 | $253 | $11 |
| Hydrocodone-Acetaminophen | 33 | $210 | $6 |
| Fluconazole | 12 | $186 | $16 |
2016: 26 drugs
| Vesicare | 57 | $28,605 | $502 |
| Myrbetriq | 56 | $24,175 | $432 |
| Elmiron | 18 | $14,059 | $781 |
| Cialis | 41 | $12,765 | $311 |
| Rapaflo | 40 | $11,830 | $296 |
| Tamsulosin | 197 | $5,665 | $29 |
| Avodart | 23 | $5,119 | $223 |
| Potassium Citrate Er | 44 | $4,145 | $94 |
| Finasteride | 176 | $4,130 | $23 |
| Dutasteride | 31 | $3,531 | $114 |
| Alfuzosin Hcl Er | 88 | $1,831 | $21 |
| Oxybutynin Chloride Er | 30 | $1,704 | $57 |
| Nitrofurantoin | 24 | $1,568 | $65 |
| Testosterone | 12 | $1,223 | $102 |
| Testosterone Cypionate | 13 | $1,105 | $85 |
| Nitrofurantoin Mono-Macro | 28 | $990 | $35 |
| Doxazosin Mesylate | 27 | $949 | $35 |
| Bicalutamide | 30 | $803 | $27 |
| Oxybutynin Chloride | 12 | $784 | $65 |
| Cephalexin | 58 | $581 | $10 |
| Levofloxacin | 32 | $578 | $18 |
| Ciprofloxacin | 58 | $431 | $7 |
| Hydrocodone-Acetaminophen | 28 | $263 | $9 |
| Fluconazole | 16 | $200 | $12 |
| Sulfamethoxazole-Trimethoprim | 16 | $129 | $8 |
| Amoxicillin-Clavulanate Potass | 12 | $112 | $9 |
2015: 24 drugs
| Vesicare | 51 | $23,465 | $460 |
| Androgel | 18 | $14,238 | $791 |
| Myrbetriq | 39 | $13,500 | $346 |
| Avodart | 46 | $11,942 | $260 |
| Rapaflo | 33 | $9,200 | $279 |
| Tamsulosin | 252 | $7,767 | $31 |
| Toviaz | 19 | $7,548 | $397 |
| Elmiron | 17 | $6,911 | $407 |
| Cialis | 28 | $6,005 | $214 |
| Enablex | 16 | $5,841 | $365 |
| Potassium Citrate Er | 33 | $4,532 | $137 |
| Finasteride | 159 | $2,839 | $18 |
| Doxazosin Mesylate | 54 | $1,457 | $27 |
| Oxybutynin Chloride Er | 29 | $1,452 | $50 |
| Alfuzosin Hcl Er | 80 | $1,205 | $15 |
| Nitrofurantoin Mono-Macro | 24 | $906 | $38 |
| Nitrofurantoin | 28 | $815 | $29 |
| Levofloxacin | 38 | $681 | $18 |
| Oxybutynin Chloride | 15 | $675 | $45 |
| Cephalexin | 56 | $483 | $9 |
| Bicalutamide | 18 | $401 | $22 |
| Ciprofloxacin | 48 | $256 | $5 |
| Hydrocodone-Acetaminophen | 15 | $102 | $7 |
| Sulfamethoxazole-Trimethoprim | 17 | $82 | $5 |
2014: 24 drugs
| Vesicare | 64 | $23,157 | $362 |
| Avodart | 90 | $21,554 | $239 |
| Elmiron | 27 | $20,757 | $769 |
| Androgel | 20 | $16,105 | $805 |
| Myrbetriq | 26 | $7,364 | $283 |
| Enablex | 20 | $6,041 | $302 |
| Rapaflo | 27 | $5,301 | $196 |
| Tamsulosin | 229 | $5,180 | $23 |
| Potassium Citrate Er | 27 | $4,226 | $157 |
| Toviaz | 22 | $4,166 | $189 |
| Finasteride | 120 | $2,250 | $19 |
| Nitrofurantoin Mono-Macro | 34 | $1,942 | $57 |
| Alfuzosin Hcl Er | 62 | $1,744 | $28 |
| Doxazosin Mesylate | 56 | $1,416 | $25 |
| Nitrofurantoin | 35 | $1,256 | $36 |
| Oxybutynin Chloride | 22 | $785 | $36 |
| Bicalutamide | 20 | $621 | $31 |
| Cephalexin | 62 | $574 | $9 |
| Phenazopyridine | 12 | $562 | $47 |
| Ciprofloxacin | 64 | $305 | $5 |
| Levofloxacin | 15 | $258 | $17 |
| Hydrocodone-Acetaminophen | 27 | $213 | $8 |
| Terazosin | 13 | $198 | $15 |
| Sulfamethoxazole-Trimethoprim | 21 | $123 | $6 |
2013: 22 drugs
| Elmiron | 31 | $25,552 | $824 |
| Vesicare | 86 | $23,452 | $273 |
| Androgel | 20 | $10,695 | $535 |
| Avodart | 52 | $9,823 | $189 |
| Rapaflo | 34 | $5,335 | $157 |
| Enablex | 17 | $4,426 | $260 |
| Tamsulosin | 194 | $4,101 | $21 |
| Potassium Citrate | 19 | $2,779 | $146 |
| Myrbetriq | 11 | $2,435 | $221 |
| Alfuzosin | 57 | $1,910 | $34 |
| Finasteride | 88 | $1,785 | $20 |
| Nitrofurantoin Mono-Macro | 30 | $1,651 | $55 |
| Oxybutynin Chloride Er | 12 | $973 | $81 |
| Bicalutamide | 22 | $857 | $39 |
| Nitrofurantoin | 23 | $788 | $34 |
| Cephalexin | 56 | $654 | $12 |
| Doxazosin Mesylate | 40 | $492 | $12 |
| Oxybutynin Chloride | 20 | $462 | $23 |
| Ciprofloxacin | 56 | $309 | $6 |
| Terazosin | 11 | $169 | $15 |
| Allopurinol | 13 | $108 | $8 |
| Diazepam | 12 | $94 | $8 |
Money from drug and device companies
$2,381 in 2025
| 2025 | 20 | 91 | None | $2,381 |
| 2024 | 15 | 49 | None | $1,267 |
| 2023 | 19 | 59 | None | $1,749 |
| 2022 | 18 | 63 | None | $1,656 |
| 2021 | 20 | 44 | None | $928 |
| 2020 | 16 | 37 | None | $801 |
| 2019 | 19 | 116 | None | $1,644 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $975 | 34 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $241 | 7 payments
|
| Abbvie | Botox | $183 | 8 payments
|
| Accord Healthcare | Camcevi | $164 | 9 payments
|
| Novartis Pharmaceuticals | Pluvicto | $105 | 4 payments
|
| Verity Pharmaceuticals | Tlando | $96 | 5 payments
|
See all 91 published payments
| Sumitomo Pharma America | Meals · 2025-12-22 | Gemtesa | $8 |
| Ferring Pharmaceuticals | Meals · 2025-12-16 | Adstiladrin | $21 |
| Abbvie | Meals · 2025-12-11 | Lupron Depot | $14 |
| Sumitomo Pharma America | Meals · 2025-12-03 | Gemtesa | $38 |
| Sumitomo Pharma America | Meals · 2025-11-21 | Gemtesa | $40 |
| Sumitomo Pharma America | Meals · 2025-11-11 | Gemtesa | $22 |
| Coloplast | Meals · 2025-11-11 | Luja Coude | $22 |
| Accord Healthcare | Meals · 2025-11-10 | Camcevi | $16 |
| 180 Medical | Meals · 2025-11-05 | None | $22 |
| Sumitomo Pharma America | Meals · 2025-11-02 | Gemtesa | $45 |
| Sumitomo Pharma America | Meals · 2025-10-30 | Gemtesa | $18 |
| Verity Pharmaceuticals | Meals · 2025-10-29 | Tlando | $15 |
| Janssen Biotech | Meals · 2025-10-28 | Erleada | $31 |
| Antares Pharma | Meals · 2025-10-21 | Xyosted | $20 |
| Sumitomo Pharma America | Meals · 2025-10-16 | Gemtesa | $36 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Pluvicto | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-13 | None | $25 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $36 |
| Verity Pharmaceuticals | Meals · 2025-10-07 | Tlando | $24 |
| Accord Healthcare | Meals · 2025-10-01 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-09-25 | Gemtesa | $40 |
| Accord Healthcare | Meals · 2025-09-23 | Camcevi | $8 |
| Sumitomo Pharma America | Meals · 2025-09-19 | Gemtesa | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-16 | None | $28 |
| Sumitomo Pharma America | Meals · 2025-09-11 | Gemtesa | $13 |
| Verity Pharmaceuticals | Meals · 2025-09-09 | Tlando | $16 |
| Abbvie | Meals · 2025-09-08 | Lupron Depot | $21 |
| Sumitomo Pharma America | Meals · 2025-09-05 | Gemtesa | $38 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-02 | Nubeqa | $22 |
| Ferring Pharmaceuticals | Meals · 2025-08-23 | Adstiladrin | $16 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Pluvicto | $19 |
| Sumitomo Pharma America | Meals · 2025-08-13 | Gemtesa | $38 |
| Verity Pharmaceuticals | Meals · 2025-08-13 | Tlando | $23 |
| Astellas Pharma US | Meals · 2025-08-12 | Xtandi | $25 |
| Abbvie | Meals · 2025-08-06 | Botox | $32 |
| Accord Healthcare | Meals · 2025-08-04 | Camcevi | $9 |
| Sumitomo Pharma America | Meals · 2025-07-31 | Gemtesa | $35 |
| Antares Pharma | Meals · 2025-07-24 | Xyosted | $27 |
| Sumitomo Pharma America | Meals · 2025-07-22 | Gemtesa | $14 |
| Abbvie | Meals · 2025-07-21 | Lupron Depot | $19 |
| Verity Pharmaceuticals | Meals · 2025-07-21 | Tlando | $18 |
| Accord Healthcare | Meals · 2025-07-17 | Camcevi | $26 |
| Sumitomo Pharma America | Meals · 2025-07-09 | Gemtesa | $36 |
| Progenics Pharmaceuticals | Meals · 2025-07-09 | Pylarify | $21 |
| Ferring Pharmaceuticals | Meals · 2025-06-30 | Adstiladrin | $19 |
| Sumitomo Pharma America | Meals · 2025-06-29 | Gemtesa | $10 |
| Coloplast | Meals · 2025-06-24 | Luja Coude | $17 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Gemtesa | $16 |
| Endo USA | Meals · 2025-06-08 | Xiaflex | $29 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Pluvicto | $32 |
| Accord Healthcare | Meals · 2025-06-04 | Camcevi | $22 |
| Sumitomo Pharma America | Meals · 2025-05-28 | Gemtesa | $39 |
| Abbvie | Meals · 2025-05-21 | Botox | $25 |
| Sumitomo Pharma America | Meals · 2025-05-16 | Gemtesa | $17 |
| Pfizer | Meals · 2025-05-13 | Xtandi | $22 |
| Agiliti Surgical | Meals · 2025-05-13 | Sonablate Hifu | $22 |
| Ferring Pharmaceuticals | Meals · 2025-05-12 | Adstiladrin | $21 |
| Sumitomo Pharma America | Meals · 2025-05-09 | Gemtesa | $31 |
| Sumitomo Pharma America | Meals · 2025-05-02 | Gemtesa | $41 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $41 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Pluvicto | $34 |
| Abbvie | Meals · 2025-04-18 | Botox | $24 |
| Coloplast | Meals · 2025-04-15 | Luja Coude | $17 |
| Progenics Pharmaceuticals | Meals · 2025-04-14 | Pylarify | $15 |
| Sumitomo Pharma America | Meals · 2025-04-07 | Gemtesa | $39 |
| Ferring Pharmaceuticals | Meals · 2025-04-07 | Adstiladrin | $17 |
| Accord Healthcare | Meals · 2025-04-03 | Camcevi | $24 |
| Astellas Pharma US | Meals · 2025-03-31 | Xtandi | $21 |
| Sumitomo Pharma America | Meals · 2025-03-26 | Gemtesa | $26 |
| Abbvie | Meals · 2025-03-24 | Botox | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-24 | Nubeqa | $27 |
| ConvaTec | Meals · 2025-03-21 | Gentlecath | $23 |
| Janssen Biotech | Meals · 2025-03-18 | Erleada | $25 |
| Accord Healthcare | Meals · 2025-03-17 | Camcevi | $9 |
| Telix Pharmaceuticals | Meals · 2025-03-14 | Illuccix | $26 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Gemtesa | $40 |
| Ferring Pharmaceuticals | Meals · 2025-03-03 | Adstiladrin | $31 |
| Telix Pharmaceuticals | Meals · 2025-03-02 | Illuccix | $20 |
| Sumitomo Pharma America | Meals · 2025-02-27 | Gemtesa | $26 |
| Accord Healthcare | Meals · 2025-02-19 | Camcevi | $27 |
| Sumitomo Pharma America | Meals · 2025-02-14 | Gemtesa | $36 |
| Astellas Pharma US | Meals · 2025-02-11 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $23 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $18 |
| Abbvie | Meals · 2025-02-04 | Lupron Depot | $24 |
| Sumitomo Pharma America | Meals · 2025-01-29 | Gemtesa | $28 |
| Sumitomo Pharma America | Meals · 2025-01-17 | Gemtesa | $15 |
| Sumitomo Pharma America | Meals · 2025-01-14 | Gemtesa | $9 |
| Sumitomo Pharma America | Meals · 2025-01-09 | Gemtesa | $37 |
| Profound Medical | Meals · 2025-01-07 | Tulsa-Pro | $91 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,267
| Sumitomo Pharma America | Gemtesa | $367 | 13 payments
|
| Astellas Pharma US | Xtandi | $222 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $117 | 5 payments
|
| Abbvie | Lupron Depot | $113 | 5 payments
|
| Janssen Biotech | Erleada | $86 | 4 payments
|
| Immunitybio | Anktiva | $63 | 2 payments
|
| Pfizer | Xtandi | $62 | 3 payments
|
| Coloplast | Luja Coude | $57 | 2 payments
|
| Blue Earth Diagnostics | Posluma | $44 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $34 | 1 payment
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $26 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $23 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Antares Pharma | Xyosted | $15 | 1 payment
|
2023: $1,749
| Astellas Pharma US | Xtandi | $420 | 17 payments
|
| Sumitomo Pharma America | Gemtesa | $332 | 13 payments
|
| Janssen Biotech | Erleada | $187 | 4 payments
|
| Edap Technomed | None | $125 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $113 | 3 payments
|
| Agiliti Surgical | Sonablate | $99 | 1 payment
|
| Pfizer | Xtandi | $70 | 4 payments
|
| Profound Medical | Tulsa-Pro | $65 | 1 payment
|
| Abbvie | Lupron Depot | $57 | 3 payments
|
| Tolmar | Jatenzo | $41 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $39 | 2 payments
|
| Ethicon US | Vistaseal | $38 | 1 payment
|
| Amgen | Xgeva | $35 | 1 payment
|
| Coloplast | Speedicath | $28 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $25 | 1 payment
|
| Antares Pharma | Nocdurna | $21 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $20 | 1 payment
|
| Kowa Pharmaceuticals America | Seglentis | $19 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $16 | 1 payment
|
2022: $1,656
| Astellas Pharma US | Myrbetriq | $523 | 18 payments
|
| Dendreon Pharmaceuticals | Provenge | $310 | 12 payments
|
| Urovant Sciences | Gemtesa | $245 | 8 payments
|
| Antares Pharma | Nocdurna | $130 | 5 payments
|
| Janssen Biotech | Erleada | $125 | 3 payments
|
| UroGen Pharma | Jelmyto | $39 | 2 payments
|
| Allergan | Botox | $34 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $34 | 2 payments
|
| Accord Healthcare | Camcevi | $32 | 2 payments
|
| Abbvie | Lupron Depot | $27 | 1 payment
|
| Amgen | Xgeva | $25 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $22 | 1 payment
|
| 180 Medical | None | $21 | 1 payment
|
| Myovant Sciences | Orgovyx | $20 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $17 | 1 payment
|
| Kowa Pharmaceuticals America | Seglentis | $17 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $17 | 1 payment
|
2021: $928
| Astellas Pharma US | Myrbetriq | $343 | 16 payments
|
| Amgen | Prolia | $101 | 4 payments
|
| Urovant Sciences | Gemtesa | $81 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $57 | 3 payments
|
| Janssen Biotech | Erleada | $46 | 2 payments
|
| Allergan | Botox | $31 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $25 | 1 payment
|
| AbbVie | Lupron Depot | $23 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $23 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $22 | 1 payment
|
| TherapeuticsMD | Imvexxy | $21 | 1 payment
|
| Urogen Pharma | Jelmyto | $21 | 1 payment
|
| 180 Medical | Speedicath | $20 | 1 payment
|
| Antares Pharma | Xyosted | $20 | 1 payment
|
| EMD Serono | None | $19 | 1 payment
|
| AngioDynamics | Nanoknife | $17 | 1 payment
|
| Axonics | Axonics R-Snm System | $17 | 1 payment
|
| Clarus Therapeutics | Jatenzo | $17 | 1 payment
|
| Myovant Sciences | Orgovyx | $13 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $12 | 1 payment
|
2020: $801
| Astellas Pharma US | Xtandi | $341 | 12 payments
|
| Janssen Biotech | Erleada | $84 | 5 payments
|
| Antares Pharma | Otrexup | $80 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $37 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $35 | 2 payments
|
| Coloplast | Speedicath | $33 | 2 payments
|
| Amgen | Prolia | $28 | 1 payment
|
| Foundation Medicine | Foundationone | $24 | 1 payment
|
| AbbVie | Lupron Depot | $24 | 1 payment
|
| NeoTract | Urolift | $22 | 1 payment
|
| Zyla Life Sciences | Sprix | $20 | 1 payment
|
| Allergan | Botox | $19 | 1 payment
|
| Photocure | Cysview | $15 | 1 payment
|
| 180 Medical | Rochester Magic3 | $14 | 1 payment
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $13 | 1 payment
|
| Assertio Therapeutics | Zipsor | $12 | 1 payment
|
2019: $1,644
| Astellas Pharma US | Myrbetriq | $256 | 14 payments
|
| Janssen Biotech | Erleada | $231 | 21 payments
|
| Zyla Life Sciences | Zorvolex | $206 | 26 payments
|
| Amgen | Prolia | $197 | 8 payments
|
| Pfizer | Xtandi | $138 | 16 payments
|
| Dendreon Pharmaceuticals | Provenge | $105 | 4 payments
|
| AbbVie | Lupron Depot | $62 | 3 payments
|
| Coloplast | Speedicath | $60 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $55 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $47 | 2 payments
|
| 180 Medical | Gentlecath | $45 | 3 payments
|
| TOLMAR Pharmaceuticals | Eligard | $43 | 2 payments
|
| TherapeuticsMD | Imvexxy | $41 | 2 payments
|
| Antares Pharma | Xyosted | $38 | 2 payments
|
| Allergan | Botox | $35 | 2 payments
|
| Boston Scientific | General Bph | $24 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $21 | 1 payment
|
| Ferring Pharmaceuticals | Firmagon | $20 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1912070889
- Licence
- CA A60360California A60360: Current · expires 2028-04-30
- Trained
- Stanford University School of Medicine, 1994
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2088P0231X (2088P0231X); Urology (208800000X)
- Mailing address
- 2581 Samaritan Drive, San Jose, CA, 95124
- NPI first listed
- 2006-11-16
- NPI last updated
- 2025-09-11
This is when the NPI record was last certified, not a medical board exam.